×

RNS Number : 8187C

Character Group PLC

24 January 2018

 

 

 

 

 

THE CHARACTER GROUP PLC

 ("Character", "Group" or "Company")

 

Designers, developers and international distributor of toys, games and giftware

 

Two Toy of the Year Awards for Character

 

London: Wednesday 24 January 2018: The Character Group plc (AIM: CCT) is delighted to announce that its principal trading subsidiary, Character Options Limited ("Character Options"), is celebrating not one, but two, successes at the annual Toy Industry Awards held last night (Tuesday 23 January 2018) at The London Toy Fair.

 

Each year the Toy Retailers Association comes together to announce which toys were most successful in the previous 12 months, with several awards being granted within their own categories.  Character Options was announced the winner of two: Best Electronic Toy for the Laser X Dual Pack, manufactured by NSI International Inc., and Best Action Toy for The Original Stretch Armstrong manufactured under licence from Hasbro.  Each of these toys were also awarded the status of Dream Toys in November 2017.  http://www.rns-pdf.londonstockexchange.com/rns/8187C_-2018-1-24.pdf

Jerry Healy, Group Marketing Director, said;

"The Toy Industry Awards night is a very important occasion as it gives credit to the 'best in class' toys of the previous year.  Everyone at Character is therefore delighted to once again be awarded two of these important accolades." 

Jon Diver, Joint MD at Character, added;

"The success also signifies the prospects for the year ahead of these two brands.  Laser X was successful from the moment it launched last July and, this year we will be extending the brand with two further toy lines, the Laser X Battling Tower and the Laser X Long Range Blaster.  Stretch Armstrong has now developed into a full product range of characters, including iconic figures from the past, Vac Man and the Stretch Monster and is one of Characters' fastest growing brands."

Kiran Shah, Joint MD at Character, also commented:

 

"The London Toy Fair this week is proving to be another great expo for us -we are currently exhibiting our full range of 2018 products and the feedback we are receiving from customers and trade visitors to the London Toy Fair is very encouraging.  We are confident that the performance of our core ranges and these new introductions will result in further growth in demand for our products, in the calendar year ahead."

 

 

ENQUIRIES:

The Character Group plc Jon Diver, Joint Managing Director Kiran Shah, Joint Managing Director & Group Finance Director Jerry Healy, Group Marketing Director

 

Office:      +44 (0) 208 329 3377 Mobile:    +44 (0) 7956 278522 (KS) Mobile:    +44 (0) 7831 802219 (JD) Email:  [email protected]

 

FTSE sector:  leisure: FTSE AIM All-share: symbol: CCT.L Market cap: £96m Copies of this statement can also be viewed at www.thecharacter.com  Product ranges can be viewed at www.character-online.co.uk  Email: [email protected]
Panmure Gordon (Nominated Adviser and Joint Broker) Andrew Godber, Investment Banking Tom Salvesen, Corporate Broking Tel:  +44 (0) 20 7886 2500
Allenby Capital Limited (Joint Broker) Nick Athanas Katrina Perez Tel:  +44 (0) 20 3328 5656
TooleyStreet Communications Limited (Investor and media relations) Fiona Tooley Tel:  +44 (0) 7785 703523 Email: [email protected]
Evolution PR (Trade Press enquiries) Michele Bates, Managing Director Tel: +44 (0)1327 227010 Mobile: +44 (0) 7725 616059 Email: [email protected]

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRABIMJTMBJTBBP

Close

×

RNS Number : 4523C

APC Technology Group PLC

22 January 2018

 

22 January 2018

 

 

APC Technology Group PLC

 ("APC" or the "Company")

 

APC to distribute 3D PLUS space components in UK

 

APC Technology Group PLC (AIM: APC), the design, specification and distributor of specialist technologies and electronic components, has signed an agreement to become the UK and Ireland distributor for 3D PLUS, a world leading manufacturer of advanced high density 3D microelectronics products for space applications.

 

3D PLUS, a Heico Company (NYSE: HEI), has an impressive 18 year' heritage within the space sector, achieving preferred supplier status for the European Space Agency and sending more than 125,000 modules into space.

 

APC's high reliability component division, APC Hi-Rel, has significant experience in designing in components into space programmes including ExoMars, BepiColombo and EarthCARE. The addition of 3D PLUS products enhances APC's range of space-qualified peripheral products such as DC-DC converters, optocouplers, crystal oscillators, capacitors, diodes and connectors – to now include 3D PLUS memory, interface and point of load converter products.

 

Patrice Benard of 3D Plus, said:

 

"APC Hi-Rel has a long history of working with organisations within the space, defence and medical sectors, which perfectly compliments our extensive product range. Their technical and engineering expertise, and strong reputation within the industry, will be an asset to designing in 3D PLUS products to bring breakthrough advantages to customers' electronic designs".

 

Richard Hodgson, CEO of APC Technology Group, commented:

 

"The combination of our existing space technologies, the premier space products that 3D PLUS bring, our prestigious customers and APC's experienced and knowledgeable team, gives us a great base for expansion in this exciting market.

 

As we set out in our results presentation, we are concentrating on three main growth drivers: growth through increased bookings from our existing technologies, in particular those that sit in high growth markets; growth through the signing of new complementary product lines; and growth through targeted bolt-on acquisitions. We have just announced our first bolt on acquisition and the signing of 3D PLUS demonstrates real traction in the signing of new technologies."

 

 More information on the 3D PLUS range of space products visit: http://apcplc.com/news-posts/apc-hi-rel-broadens-components-range-space-applications/

 

 

Enquiries:

 

APC Technology Group PLC                                                                               +44 (0) 330 313 3220

Richard Hodgson, Chief Executive                                                                   www.apcplc.com

Michael Thompson, Finance Director                           

                                                                                                                            

Stockdale Securities Limited (Nominated Adviser and Broker)                +44 (0)20 7601 6100

Mark Brown / Antonio Bossi / Edward Thomas

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRABRGDBBXBBGIC

Close

×

RNS Number : 3676C

Cronin Group PLC

19 January 2018

 

19 January 2018

Cronin Group Plc

("Cronin Group")

Publication of Scientific Paper

Publication in international weekly science journal, Science, of digitization of multi-step organic synthesis

 

Cronin Group, the AIM listed company focusing on digitizing chemistry, announces that its scientific founder and Non-Executive director, Professor Lee Cronin, has published in Science, the international weekly science journal, a paper demonstrating the digitization of chemistry for synthesis on demand.

 

The manufacture of active pharmaceutical ingredients ("APIs") is vital for modern healthcare, yet critical drugs are regularly manufactured for a finite period in a limited number of sites. To alleviate this issue, Professor Cronin proposes a concept whereby the large-scale manufacturing process of complex fine chemicals, such as APIs, is augmented by distributed, point-of-use manufacturing in self-contained cartridges requiring limited user interaction to produce the desired products on demand. 

 

Using some 3D printing methodologies covered in Cronin Group's patent US9643152, "Apparatus and methods for the preparation of reaction vessels", the authors demonstrated the translation of benchscale synthesis procedures into a step-by-step workflow that could be used to create digital designs for custom reactionware that can be fabricated by using three-dimensional (3D) printing technologies.

 

Professor Lee Cronin, Non-Executive director of Cronin Group, commented: "I'm very excited about the different market opportunities which the digitization of chemistry has the potential to open up."

 

The full manuscript of "Digitization of multi-step organic synthesis in reactionware for on-demand pharmaceuticals" can be found at http://science.sciencemag.org/content/359/6373/314.

 

 

For further information:

 

Cronin Group Plc	www.croningroupplc.com
Mark Warne, Executive Chairman	T:  0141 465 6871
Stockdale Securities Limited	T: 020 7601 6100
Tom Griffiths/Edward Thomas

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAKMGMMRLMGRZG

Close

×

RNS Number : 9367B

Genedrive PLC

16 January 2018

 

For release: 16 January 2018

 

genedrive plc ("genedrive" or the "Company")

 

First Successful Field Evaluation of Genedrive® HCV Assay in Africa

 

Performance Study in Johannesburg Demonstrated 100% Sensitivity and Specificity

 

genedrive plc, (AIM: GDR), the near patient molecular diagnostics company, today announces successful results of the first field study of its Genedrive® Hetaptitis C (HCV) ID Kit in Africa.

 

The study, performed in Johannesburg at Lancet Laboratories, one of the leading private pathology testing laboratories operating throughout Africa, was designed to verify genedrive HCV's assay performace across the diverse genotypes which are prevalent in Africa compared to Europe.  

 

In a cohort of 130 clinical samples from South Africa, Kenya, Ghana, Nigeria, Uganda, and other Sub-Saharan countries, the Genedrive® HCV ID Kit demonstrated sensitivity and specificity of 100% compared to the Abbott M2000 HCV Real time assay as a reference.  The cohort was composed mostly of HCV genotypes 1a, 4, and 1b, with the remaining 16% samples from genotypes 2, 3, and 5.  The test also demonstrated efficiency of 95.4% (result achieved first attempt).

 

"These positive results with the genedrive HCV assay in customer hands on local samples confirms that our good clinical validation performance can be translated into real-world settings where the test will be used, " said David Budd, Chief Executive Officer of genedrive plc. "Our test is the first to market as a decentralised qualitative molecular HCV test for use at the point of need.  We remain confident it can play an important role in the diagnosis and management of the disease in Africa and in other territories where access to centralized laboratories is limited."  

 

Dr Allison Glass, Pathologist-in-Charge at Lancet Laboratories Johannesburg, commented, "Our trained laboratory staff found the Genedrive® HCV system and kit easy to operate, and, compared to the Abbott M2000 platform, required no maintenance, had a small laboratory foot print and faster processing time. Many of the original samples were haemolysed but produced valid results first time, demonstrating the robustness of using PCR direct from plasma. The genedrive HCV kit has the potential to decentralise clinical management of chronic HCV, which may result in the expansion of treatment programmes to rural areas of resource-limited countries."

 

The study follows the recent announcement that genedrive plc has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of Sysmex Corporation, a world leader in clinical laboratory systemization and solutions, for the Genedrive® HCV ID Kit and Genedrive® platform in the EMEA region with an initial focus on Africa. genedrive plc also entered into a distribution agreement with Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region.

 

 

–  Ends  –

 

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

Matthew Fowler: CFO

 

Sysmex Europe GmbH

Fernando Andreu: Senior Executive Officer                                                                +49 40 527 260

Jens Behrens: Director, Marketing Communications

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected] 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV ID Kit has recived CE marking. Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

About Sysmex Europe

Sysmex Europe GmbH (SEG), located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices – designated a Great Place to Work® in 2014 and 2016 – we serve our affiliates, distributors and customers throughout EMEA – Europe, the Middle East and Africa. Globally we employ around 8000 staff, of whom 1300 work in the EMEA region.

Sysmex is the global leader in haematology and a renowned specialist in haemostasis, urinalysis, and laboratory automation. As our expertise in the interdependency of disease and medical disciplines grows, we are growing to cover other pressing areas such as oncology, flow cytometry, liquid biopsy and essential healthcare in resource-poor regions. This is allowing us to deliver clinical value that primary healthcare workers such as physicians, surgeons and other specialists can use directly to deliver better diagnostics, treatment and monitoring, and so improve the quality of life of their patients. Everything we do is driven by a single mission: Shaping the advancement of healthcare. For more information about Sysmex Europe, please visit www.sysmex-europe.com, and for details on Sysmex Africa www.sysmex.co.za

 

About Hepatitis C

Hepatitis C is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic hepatitis C, and more than 350,000 people die yearly from hepatitis C related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate Hepatitis C.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAXFSFAXPEFF

Close

×

RNS Number : 9469B

Midatech Pharma PLC

16 January 2018

 

 

16 January 2018

 

Midatech Pharma PLC

("Midatech", "Company" or "Group")

 

Midatech and UCSF receive IND approval for DIPG treatment MTX110

 

– First treatment in patients in US expected as scheduled in Q1 2018

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces approval of the investigational new drug (IND) application from the US Food and Drug Administration (FDA) to conduct a study of MTX110, an investigational nano-inclusion product, for the treatment of the fatal childhood brain cancer DIPG.

 

This disease occurs mainly in young children and has a median survival of nine months. With no treatment currently approved, the approval of this trial could be a big step towards developing a treatment for this cancer.

 

MTX110 was selected based on both independent and Midatech research that identified the active ingredient as the most potent compound of 83 tested against human DIPG tumour cells.  Midatech has swiftly brought the compound from initial formulation stage at the end of 2015 to this clinical trial in 2018.

 

The study will be conducted at leading treatment centres in UCSF in San Francisco, and the Memorial Sloan Kettering Cancer Center in New York. It has also been provided on a compassionate use basis to patients and to date it has been well tolerated.  This study is expected to read out towards the end of 2019 and, if successful, expedited approval will be sought from international regulators.

 

Commenting on the approval of MTX110, Dr. Jim Philips, CEO of Midatech Pharma, said: "Midatech has worked hard to rapidly develop and bring MTX110 through to this clinical trial.  We have seen compelling data for MTX110 in pre-clinical models and we are excited by the potential for this to be evidenced in patients as well. We are looking forward to potentially demonstrating the drug's efficacy in this disease, and making a difference to the children suffering from this devastating cancer for which palliative options are currently the only choice.  MTX110 is one of our three priority programmes and we look forward to reporting back on progress in due course."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected] 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and other therapeutic areas, and marketing these through its established US commercial operation which includes four cancer care supportive products and two further co-promoted products.  Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions.  The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

REAFMGMMZKNGRZZ

Close

×

RNS Number : 8093B

e-Therapeutics plc

15 January 2018

 

e-Therapeutics

('e-Therapeutics' or the 'Company')

 

e-Therapeutics to collaborate with Intellegens and Biorelate
to enhance and extend its AI technology capabilities

Oxford, UK, 15 January 2018: e-Therapeutics, a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, today announces agreements with Intellegens and Biorelate. Both companies have artificial intelligence (AI) tools which, after pilot studies, have been proven to enhance ETX's existing computational NDD technology. No financial details were disclosed.

 

Intellegens is a spin-out from the University of Cambridge that has developed a unique AI method for training neural networks from incomplete data. The collaboration will allow e-Therapeutics to apply Intellegens' technology to the predication and error correction of large-scale biological and chemical data. This will enable neural networks to be trained on the sparse data typical of biological and chemical problems. Application of the technology will result in the enhancement of e-Therapeutics' existing proprietary databases facilitating greater coverage of chemical space. In addition, it will be used to develop a novel computationally guided approach to medicinal chemistry.

 

Manchester-based Biorelate provides biomedical knowledge by using AI to create curated databases from the analysis of published literature. Its cutting edge technology uniquely combines natural language processing (NLP) and machine learning with human expert curation. The result is the extraction of structured biological knowledge from the wide body of expert journals. The aim of the collaboration is to directly feed this knowledge into e-Therapeutics' Network-Driven Drug Discovery engine facilitating the pursuit of novel disease mechanisms.

 

Dr Jonny Wray, Head of Discovery Informatics at e-Therapeutics said "I'm excited we're entering into partnership with these two companies. We already utilize machine learning heavily in our discovery platform to augment empirical biological and chemical data. These partnerships will enhance and extend our internal capabilities via collaborations with companies at the cutting edge of AI research and application."

 

Dr Gareth Conduit, founder of Intellegens, said: "We are very excited to be entering into this relationship with e-Therapeutics. We believe our novel deep learning technology, specifically suited to sparse data problems, will significantly improve the data and enable more opportunities to be investigated within e-Therapeutics' Network-Driven Drug Discovery approach"

 

Dr Daniel G Jamieson, founder & CEO of Biorelate, said: "The partnership with e-Therapeutics is an important milestone in our on-going mission to curate truths in biomedicine. We will be supporting e-Therapeutics' drive to better understand how complex diseases work. As biomedical knowledge continues to expand, the need to harness this and better understand what is already known is now greater than ever."

 

-Ends-

For further information, please contact:

 

e-Therapeutics plc Ray Barlow, CEO Jonny Wray, Head of Discovery Informatics	Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
Instinctif Partners Melanie Toyne Sewell/Alex Shaw	Tel: +44 (0) 207 457 2020 Email: [email protected]

 

 

Notes to Editors

 

About e-Therapeutics plc

 

e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.  

 

Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.

 

For more information about the Company, please visit www.etherapeutics.co.uk

 

About Intellegens

Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence method for training neural networks from incomplete data.

 

The technique, developed in the Department of Physics, has been applied to drug discovery and material design, but as the technique is generic it can be applied to many domains where there is big, incomplete data.

 

For more information, please visit intellegens.ai or contact [email protected].

 

About Biorelate

 

Biorelate is a venture-backed AI start-up, based in Manchester, UK, with a mission to curate truths in biomedicine.

 

By providing scientists with the necessary components to tackle biomedicine's biggest unanswered questions they aim to propel life sciences research into a new era of big data analysis.

 

For more information, please visit www.biorelate.com or contact [email protected].

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUSSARWRAAAUR

Close

×

RNS Number : 2884B

Midatech Pharma PLC

09 January 2018

 

 

 

 

9 January 2018

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

 

Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces it has received oral confirmation from Polish regulators that its first in-human study of its sustained release product octreotide MTD201 is approved.  Formal written confirmation of the approval is expected within the next two weeks.

 

Q-Octreotide (MTD201) is Midatech's treatment for carcinoid cancer and acromegaly built on its Q-SpheraTM sustained release platform technology. The somatostatin analogue treatment for carcinoid cancer and acromegaly is being developed as the first alternative version of the commercial leading product, Sandostatin® LAR (SLAR). During its pre-clinical programme, data suggested that Q-Octreotide has an equivalent profile to the Novartis SLAR and may offer some important advantages to clinicians and patients. Midatech believes that if these data are confirmed in the upcoming study Q-Octreotide could capture up to a 5% share of the market for SLAR, which is worth $2bn annually1.

 

This potentially pivotal study comprises an initial exploratory phase which is expected to complete by mid-2018. The final confirmatory phase is expected to complete in H2 2018.

 

The decision to take Q-Octreotide to commercial scale will be taken following the interim data. Assuming positive clinical data, Midatech anticipates a launch as early as 2020.

 

Commenting on the news, Dr Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "This is a major milestone for Midatech and we are pleased to start dosing in subjects soon. We have seen compelling data for MTD201 in pre-clinical models and we are excited by the potential for this to be evidenced in patients as well. This trial will provide useful data not only for MTD201, which is one of our top three priority programmes, but also for our sustained release technology platform that is being evaluated for follow-on products."

 

1 Novartis.com; Ipsen.com

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Nick Brown

Tel: +44 (0)20 3709 5700

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and other therapeutic areas, and marketing these through its established US commercial operation which includes four cancer care supportive products and two further co-promoted products.  Midatech's strategy is to internally develop oncology products, and to drive growth both organically and through strategic acquisitions.  The Company's R&D activities are focused on three innovative platform technologies to deliver drugs at the "right time, right place": gold nanoparticles ("GNPs") to enable targeted delivery; Q-Sphera polymer microspheres to enable sustained release ("SR") delivery; and Nano Inclusion ("NI") to provide local delivery of therapeutics, initially to the brain. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

REALFFVLLFITIIT

Close

×

RNS Number : 2881B

Xeros Technology Group plc

09 January 2018

 

RNS Reach

 

9 January 2018

 

Xeros Technology Group plc

 

Xeros unveils transformational home washing machine

 

Xeros Technology Group plc (AIM: XSG, 'the Group', 'Xeros'), the developer and provider of patented polymer based technologies with multiple commercial applications, today unveils a domestic washing machine incorporating its three new innovative technologies, at the Consumer Electronics Show in Las Vegas. This innovation has the potential to transform the $127bn global domestic laundry market, bringing environmentally sustainable cleaning into the home.

 

The technology represents a breakthrough in domestic washing, by cleaning clothes with up to 50% reductions in water, detergent and energy, whilst delivering a demonstrably superior clean.

 

The domestic machine also includes a filtering system which greatly reduces the amount of synthetic microfibers from the washing process from entering rivers and oceans. In so doing, Xeros has honoured the commitments it made to the United Nations Ocean Conference in June 2017.

 

Mark Nichols, Chief Executive of Xeros, said:

 

"We're very excited about the launch of our domestic machine at CES with its three new technologies.

 

"The global domestic laundry opportunity is enormous: 119 million machines are sold annually around the world, and the global market of both machines and detergent together has an annual retail value of $127bn.

 

"This is a key development for us. Our technologies provide a sizeable and growing group of consumers with home washing machines that are environmentally friendly, using considerably less water, detergent and power as well as providing better cleaning and fabric care."

 

The launch will showcase three new Xeros-developed technologies:

 

·      XOrb™

An evolution of the polymer technology used in Xeros' commercial laundry solution, at the heart of Xeros' home laundry system is XOrb™ technology: reusable, recyclable and safe. XOrb™ technology enables the cleaning of clothes through absorption, adsorption and mechanical action.

 

The XOrbs result in a significant reduction in water, power and chemical use and are dispensed and retrieved from the wash in the Xeros XDrum™.

 

·      XDrum™

 

The XDrum is a system which enables manufacturers to incorporate XOrb™ technology into their own-branded home washing machine designs with minimal disruption to their manufacturing process and at low cost.

 

For the first time, manufacturers will be able to offer consumers the benefits of Xeros that have previously only been available to commercial laundry operations.

 

 

·      XFiltra™

 

In response to the growing awareness of the environmental impact of harmful microparticles entering the water system from the washing of synthetic garments, Xeros has developed the XFiltra™.

 

Compatible with any home washing machine, the XFiltra includes an integrated pump, filter and dewatering device that provides a simple, low-maintenance filtration solution that cleans wash water before its release to sewage systems.

 

For a video demonstrating the technologies, please visit: https://xeroscleaning.wistia.com/medias/5b9f2zp34i 

 

Enquiries:

 

Xeros Technology Group plc Mark Nichols, Chief Executive Officer Paul Denney, Chief Financial Officer	Tel: 0114 321 6328
Instinctif Partners Adrian Duffield / Helen Tarbet / Mikael Astrand	Tel: 020 7457 2020

Notes to Editors

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes by reducing water and chemistry usage with its polymer technologies. Its patented technologies have the capacity to provide material economic, operational and sustainability improvements that are unattainable with traditional processes.  The Group is currently exploiting its intellectual property in three areas: Cleaning Technologies, Tanning Technologies and Textile Technologies. Xeros has a number of agreements in place with such international organisations as BASF, Hilton and Wollsdorf Leder.

 

Water scarcity is a global imperative. Out of the 1.3 billion km3 of water on the planet, only 0.5% is accessible by people. More than 80% of this water is from ground sources that are being rapidly depleted. Immediate problems caused by this over extraction include infrastructure collapse, with further stress being caused by pollution.

 

As a result, there are major supply implications to address, not least in the global domestic laundry market, which is estimated to use 10 trillion litres of water per annum.

 

For more information, please visit: http://www.xerostech.com/

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAFKFDDDBKBCDK

Close

×

RNS Number : 1664B

Xeros Technology Group plc

08 January 2018

 

 8 January 2018

 

Xeros Technology Group plc

 

Second Symphony Project development agreement signed

 

Xeros Technology Group plc (AIM: XSG, 'Xeros'), the developer and provider of polymer based technologies with multiple commercial applications, has signed a second Symphony Project development agreement with another leading manufacturer of commercial washing machines ('the OEM'). 

 

The OEM is a leader in commercial laundry machines with a significant presence in many major markets across the world. Xeros will incorporate its open source technology in the OEM's machine for the purposes of technical validation and testing. Following the testing phase the parties anticipate the commencement of commercial negotiations.

 

In April 2017, Xeros launched Symphony Project, providing open source access to its innovative polymer technology to manufacturers of commercial washing machines. At the Clean Show in Las Vegas in June 2017 Xeros demonstrated its first fully working prototype and in September 2017, Xeros announced its first Symphony agreement with a major global OEM.

 

Symphony Project will enable manufacturers to sell their own-branded products as well as receiving a share in the long-term savings that the Xeros technology delivers.

 

The development of Symphony Project is in line with Xeros' strategy to commercialise its technology with partners, who already have strong market positions.  It will enable the Group to make a financial return on its intellectual property and know-how with relatively low capital intensity.

 

A website providing a full explanation of Symphony Project is available here: www.symphonyproject.com

 

Mark Nichols, Chief Executive, said:

 

"This represents a further significant milestone for our Cleaning Technologies business. The scale and market presence of another OEM partner demonstrates the industry's increasing understanding and acceptance of our technology.

 

"With a proven technology, and growing demand for the sustainability, performance and economic benefits our technology delivers, Symphony Project will enable us to significantly accelerate the commercialisation of our technology."

 

Enquiries:

 

Xeros Technology Group plc Mark Nichols, Chief Executive Officer Paul Denney, Chief Financial Officer	Tel: 0114 321 6328
Jefferies International Limited (Nominated Adviser and Joint Broker) Simon Hardy / Will Soutar	Tel: 020 7029 8000
Berenberg (Joint Broker) Chris Bowman / Ben Wright / Amritha Murali	Tel: 020 3207 7800
Instinctif Partners Adrian Duffield / Helen Tarbet / James Gray	Tel: 020 7457 2020

Notes to Editors

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes by reducing water and chemistry usage with its polymer technologies.  Its patented technologies have the capacity to provide material economic, operational and sustainability improvements that are unattainable with traditional processes.  The Group is currently exploiting its intellectual property in three areas: Cleaning Technologies, Tanning Technologies and Textile Technologies. Xeros has a number of agreements in place with such international organisations as BASF, Hilton and Wollsdorf Leder.

 

For more information, please visit – http://www.xerostech.com/

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRUBAORWKAARUR

Close

×

RNS Number : 9115A

Water Intelligence PLC

04 January 2018

 

 

 

Water Intelligence plc

(the "Company")

Second National Insurance Agreement Signed

 

Water Intelligence plc announces the signing and launch of the Company's second formal national contract with one of the top 5 insurance companies in the US to provide adjusters a trusted partner to pinpoint water leaks and minimize collateral damage claims from residences and businesses.  The Company's provision of nationwide coverage through American Leak Detection (ALD), its highly regarded franchise and corporate-operated brand, allows for a nationwide execution for customers in the United States.

 

During 2017, ALD implemented its first national contract, having previously worked with insurance claims adjusters across the U.S. relying mainly on local marketing and execution from its franchisees.  In an effort to meet insurance customers' demand for a consistent nationwide business to business approach, ALD implemented a centralized channel for job assignments and billing.  During 2017 approximately 35,000 jobs originated from this central channel.  The strategy has now been enhanced further with the introduction of partnerships with product companies.  

 

Executive Chairman, Patrick DeSouza commented:  "A business to business approach will leverage our existing national footprint and reduce administrative costs for our insurance company partners.  Year one implementation went well.  In response to strong demand, we plan to do more of the same in 2018 and beyond, as the insurance market is currently seeking complete solutions for minimizing water loss through leakage and we believe we are well positioned to deliver this. We look forward to another significant increase in the amount of insurance work acquired for our corporate and franchise locations." 

 

 

Enquiries:  

Water Intelligence plc            Patrick DeSouza, Executive Chairman	Tel: +1 203 654 5426
finnCap Ltd Adrian Hargrave / Giles Rolls, corporate finance Stephen Norcross, corporate broking	Tel: +44 (0) 207 220 0500

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRBJMMTMBTMTFP

Close